Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene LabBGLC +0.22%55 Earnings Yield (Joel Greenblatt) % is -185.19% as of Jun. 2026. GuruFocus rates BGLC with a GF Score™ of 55/100 and a GF Value™ of $1.25 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,630 Chemicals companies, BioNexus Gene Lab ranks worse than 99.88% on this metric.
BioNexus Gene Lab's Enterprise Value for the quarter that ended in Jun. 2026 was $1.39 Mil.
BioNexus Gene Lab's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-2.56 Mil. BioNexus Gene Lab's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -185.19%.
The historical rank and industry rank for BioNexus Gene Lab's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
BGLC'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -783.05 Med: -2.71 Max: 1929.69
Current: -192.31
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of BioNexus Gene Lab was 1929.69%. The lowest was -783.05%. And the median was -2.71%.
BGLC's Earnings Yield (Joel Greenblatt) % is ranked worse than 99.88% of 1630
companies
in the Chemicals industry
Industry Median: 4.065
vs BGLC: -192.31
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. BioNexus Gene Lab's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
BioNexus Gene Lab Earnings Yield (Joel Greenblatt) % Related Terms
BioNexus Gene Lab Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Earnings Yield (Joel Greenblatt) % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
BioNexus Gene Labs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
BioNexus Gene Lab's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.56 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -185.19% mean?
BioNexus Gene Lab (BGLC) has a Earnings Yield (Joel Greenblatt) % of -185.19% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on BioNexus Gene Lab and its competitors. According to the industry distribution chart, BioNexus Gene Lab ranks #1628 out of 1630 companies in the Chemicals industry, placing it in the top 99.9%.
Is BioNexus Gene Lab's Earnings Yield (Joel Greenblatt) % too high?
BioNexus Gene Lab's current Earnings Yield (Joel Greenblatt) % is -185.19%. Based on the distribution chart, BioNexus Gene Lab ranks #1628 out of 1630 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Earnings Yield (Joel Greenblatt) % compare to VYST and QGAI?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #1628 out of 1630 companies for Earnings Yield (Joel Greenblatt) %. This places BioNexus Gene Lab in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 4.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Chemicals company?
The median Earnings Yield (Joel Greenblatt) % among Chemicals companies is 4.07, based on 1,630 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on BioNexus Gene Lab and its competitors. For the Chemicals industry, the median Earnings Yield (Joel Greenblatt) % is 4.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current Earnings Yield (Joel Greenblatt) % is -185.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $1.59 — trading 27.2% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -185.19%. BioNexus Gene Lab's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Earnings Yield (Joel Greenblatt) % is -185.19% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be overvalued.
The current stock price of $1.59 is trading 27.2% above its estimated GF Value™ of $1.25.
GuruFocus considers BioNexus Gene Lab to be Modestly Overvalued.
Key valuation signals for BGLC:
Earnings Yield (Joel Greenblatt) %: -185.19%
GF Value™: $1.25 vs. price of $1.59 (27.2% above fair value)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
55GF Score
Get the complete analysis for BGLC
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
